UPTRAVI® IV IS FOR THE TREATMENT OF PAH (WHO GROUP I) IN FC II-III PATIENTS WHO ARE TEMPORARILY UNABLE TO TAKE ORAL THERAPY2
- Avoid treatment disruptions when your patients are unable to take oral therapy by temporarily transitioning them from their current oral dose to IV treatment and returning to UPTRAVI® Tablets when possible2,3
Remain confident that your patients can receive UPTRAVI® treatment at home, in the hospital, and after discharge
- Expected to maintain similar UPTRAVI® efficacy and safety, with the exception of infusion-site reactions, when temporarily using UPTRAVI® IV in the hospital2,3
- Bypass re-titration when transitioning between UPTRAVI® IV and UPTRAVI® Tablets2
Administer UPTRAVI® IV twice daily by intravenous infusion at a dose that corresponds to the patient’s current dose of UPTRAVI® Tablets.
Please see complete UPTRAVI® IV dosing and administration instructions as listed in the full Prescribing Information.
UPTRAVI® IV INSTRUCTIONS FOR USE VIDEO
Watch the video below to learn more about storage, reconstitution, dilution, and administration of UPTRAVI® IV.
Select a Chapter
UPTRAVI® IV Instructions for Use Guide
Use this guide to learn about storage, reconstitution, dilution, and administration of UPTRAVI® IV.
UPTRAVI® IV Frequently Asked Questions
Get the answers to your questions about UPTRAVI® IV.
TEMPORARILY SWITCHING TO UPTRAVI® IV FROM UPTRAVI® TABLETS WAS WELL TOLERATED WITH COMPARABLE EXPOSURE TO THE ACTIVE METABOLITE
- Phase 3, prospective, multicenter, open-label, single-sequence crossover study
- Twenty patients with PAH in FC I-III† receiving a stable dose of UPTRAVI® Tablets for ≥28 days prior to enrollment were included
- Patients were monitored to assess the safety, tolerability, and pharmacokinetics (including exposure to the active metabolite ACT-333679) of switching from a stable dose of UPTRAVI® Tablets to a corresponding dose of UPTRAVI® IV and back to UPTRAVI® Tablets
- The dosing regimen for UPTRAVI® IV was selected to help patients achieve similar exposure to the active metabolite when compared with UPTRAVI® Tablets
Baseline patient characteristics (N=20)3
- Mean age: 57 years
- Female: 80%
- Etiology: idiopathic or heritable PAH (70%), PAH-CTD (20%), PAH-CHD (5%), PoPH (5%)
Comparable exposure to the active metabolite following UPTRAVI® Tablets and UPTRAVI® IV administration
- The transition from UPTRAVI® Tablets to UPTRAVI® IV and back was well tolerated: Patient tolerability was similar between UPTRAVI® IV and Tablets
- 10% of patients reported infusion-site reactions during UPTRAVI® IV administration, including infusion-site erythema/redness, pain, and swelling